1
|
Pasquevich KA, Coria LM, Ceballos A, Mazzitelli B, Rodriguez JM, Demaría A, Pueblas Castro C, Bruno L, Saposnik L, Salvatori M, Varese A, González S, González Martínez VV, Geffner J, Álvarez D, Feleder E, Halabe K, Perez Lera PE, de Oca FM, Vega JC, Lombardo M, Yerino GA, Fló J, Cassataro J. Safety and immunogenicity of a SARS-CoV-2 Gamma variant RBD-based protein adjuvanted vaccine used as booster in healthy adults. Nat Commun 2023; 14:4551. [PMID: 37507392 PMCID: PMC10382514 DOI: 10.1038/s41467-023-40272-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2023] [Accepted: 07/20/2023] [Indexed: 07/30/2023] Open
Abstract
A Gamma Variant RBD-based aluminum hydroxide adjuvanted vaccine called ARVAC CG was selected for a first in human clinical trial. Healthy male and female participants (18-55 years old) with a complete COVID-19-primary vaccine scheme were assigned to receive two intramuscular doses of either a low-dose or a high-dose of ARVAC CG. The primary endpoint was safety. The secondary objective was humoral immunogenicity. Cellular immune responses were studied as an exploratory objective. The trial was prospectively registered in PRIISA.BA (Registration Code 6564) and ANMAT and retrospectively registered in ClinicalTrials.gov (NCT05656508). Samples from participants of a surveillance strategy implemented by the Ministry of Health of the Province of Buenos Aires that were boosted with BNT162b2 were also analyzed to compare with the booster effect of ARVAC CG. ARVAC CG exhibits a satisfactory safety profile, a robust and broad booster response of neutralizing antibodies against the Ancestral strain of SARS-CoV-2 and the Gamma, Delta, Omicron BA.1 and Omicron BA.5 variants of concern and a booster effect on T cell immunity in individuals previously immunized with different COVID-19 vaccine platforms.
Collapse
Affiliation(s)
- Karina A Pasquevich
- Instituto de Investigaciones Biotecnológicas, Universidad Nacional de San Martín (UNSAM) - Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), San Martín (1650), Buenos Aires, Argentina.
- Escuela de Bio y Nanotecnologías (EByN), Universidad Nacional de San Martín, San Martín (1650), Buenos Aires, Argentina.
| | - Lorena M Coria
- Instituto de Investigaciones Biotecnológicas, Universidad Nacional de San Martín (UNSAM) - Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), San Martín (1650), Buenos Aires, Argentina
- Escuela de Bio y Nanotecnologías (EByN), Universidad Nacional de San Martín, San Martín (1650), Buenos Aires, Argentina
| | - Ana Ceballos
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA, INBIRS-CONICET, Facultad de Medicina UBA, Buenos Aires, Argentina
| | - Bianca Mazzitelli
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA, INBIRS-CONICET, Facultad de Medicina UBA, Buenos Aires, Argentina
| | - Juan Manuel Rodriguez
- Fundación Pablo Cassará - Unidad de I + D de Biofármacos, Saladillo 2452 C1440FFX, Ciudad Autónoma de Buenos Aires, Argentina
| | - Agostina Demaría
- Instituto de Investigaciones Biotecnológicas, Universidad Nacional de San Martín (UNSAM) - Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), San Martín (1650), Buenos Aires, Argentina
- Escuela de Bio y Nanotecnologías (EByN), Universidad Nacional de San Martín, San Martín (1650), Buenos Aires, Argentina
| | - Celeste Pueblas Castro
- Instituto de Investigaciones Biotecnológicas, Universidad Nacional de San Martín (UNSAM) - Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), San Martín (1650), Buenos Aires, Argentina
- Escuela de Bio y Nanotecnologías (EByN), Universidad Nacional de San Martín, San Martín (1650), Buenos Aires, Argentina
| | - Laura Bruno
- Instituto de Investigaciones Biotecnológicas, Universidad Nacional de San Martín (UNSAM) - Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), San Martín (1650), Buenos Aires, Argentina
- Escuela de Bio y Nanotecnologías (EByN), Universidad Nacional de San Martín, San Martín (1650), Buenos Aires, Argentina
| | - Lucas Saposnik
- Instituto de Investigaciones Biotecnológicas, Universidad Nacional de San Martín (UNSAM) - Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), San Martín (1650), Buenos Aires, Argentina
- Escuela de Bio y Nanotecnologías (EByN), Universidad Nacional de San Martín, San Martín (1650), Buenos Aires, Argentina
| | - Melina Salvatori
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA, INBIRS-CONICET, Facultad de Medicina UBA, Buenos Aires, Argentina
| | - Augusto Varese
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA, INBIRS-CONICET, Facultad de Medicina UBA, Buenos Aires, Argentina
| | - Soledad González
- Ministerio de Salud de la Provincia de Buenos Aires, Buenos Aires, Argentina
| | | | - Jorge Geffner
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA, INBIRS-CONICET, Facultad de Medicina UBA, Buenos Aires, Argentina
| | - Diego Álvarez
- Instituto de Investigaciones Biotecnológicas, Universidad Nacional de San Martín (UNSAM) - Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), San Martín (1650), Buenos Aires, Argentina
- Escuela de Bio y Nanotecnologías (EByN), Universidad Nacional de San Martín, San Martín (1650), Buenos Aires, Argentina
| | - Ethel Feleder
- FP CLINICAL PHARMA, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
| | - Karina Halabe
- FP CLINICAL PHARMA, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
| | - Pablo E Perez Lera
- FP CLINICAL PHARMA, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
| | - Federico Montes de Oca
- Laboratorio Pablo Cassará - Unidad de I + D de Biofármacos, Saladillo 2452 C1440FFX, Ciudad Autónoma de Buenos Aires, Argentina
| | - Julio C Vega
- Laboratorio Pablo Cassará - Unidad de I + D de Biofármacos, Saladillo 2452 C1440FFX, Ciudad Autónoma de Buenos Aires, Argentina
| | | | - Gustavo A Yerino
- FP CLINICAL PHARMA, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
| | - Juan Fló
- Laboratorio Pablo Cassará - Unidad de I + D de Biofármacos, Saladillo 2452 C1440FFX, Ciudad Autónoma de Buenos Aires, Argentina
| | - Juliana Cassataro
- Instituto de Investigaciones Biotecnológicas, Universidad Nacional de San Martín (UNSAM) - Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), San Martín (1650), Buenos Aires, Argentina.
- Escuela de Bio y Nanotecnologías (EByN), Universidad Nacional de San Martín, San Martín (1650), Buenos Aires, Argentina.
| |
Collapse
|
2
|
Di Diego Garcia F, Cabrerizo G, Paletta A, Prez PS, Varese A, Geffner J, Bello N, Fridman V, Stecher D, Ceballos A, Remes Lenicov F. Resistance to Prostaglandin E2 Promotes Monocyte Activation During Chronic HIV Infection. J Infect Dis 2023; 227:423-433. [PMID: 36482781 DOI: 10.1093/infdis/jiac480] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2022] [Revised: 11/28/2022] [Accepted: 12/07/2022] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND Monocyte activation is a driver of inflammation in the course of chronic HIV infection. Prostaglandin E2 (PGE2) is known to mediate anti-inflammatory effects, notably the inhibition of tumor necrosis factor- (TNF-) production by monocytes. We aim to investigate the effects of PGE2 on activation of monocytes in chronic HIV infection and the mechanisms through which PGE2 modulates their inflammatory signature. METHODS We recruited a group of people with HIV (PWH) and matched healthy uninfected persons. We compared plasma levels of PGE2, monocyte activation, and sensitivity of monocytes to the inhibitory actions mediated by PGE2. RESULTS We found increased plasma levels of PGE2 in PWH, and an activated phenotype in circulating monocytes, compared with uninfected individuals. Monocytes from PWH showed a significant resistance to the inhibitory actions mediated by PGE2; the concentration of PGE2 able to inhibit 50 of the production of TNF- by lipopolysaccharide-stimulated monocytes was 10 times higher in PWH compared with uninfected controls. Furthermore, the expression of phosphodiesterase 4B, a negative regulator of PGE2 activity, was significantly increased in monocytes from PWH. CONCLUSIONS Resistance to the inhibitory actions mediated by PGE2 could account, at least in part, for the inflammatory profile of circulating monocytes in PWH.
Collapse
Affiliation(s)
- Facundo Di Diego Garcia
- Instituto de Investigaciones Biomdicas en Retrovirus y SIDA, Universidad de Buenos Aires/CONICET, Buenos Aires, Argentina
| | - Gonzalo Cabrerizo
- Instituto de Investigaciones Biomdicas en Retrovirus y SIDA, Universidad de Buenos Aires/CONICET, Buenos Aires, Argentina
| | - Ana Paletta
- Instituto de Investigaciones Biomdicas en Retrovirus y SIDA, Universidad de Buenos Aires/CONICET, Buenos Aires, Argentina
| | - Paula S Prez
- Instituto de Investigaciones Biomdicas en Retrovirus y SIDA, Universidad de Buenos Aires/CONICET, Buenos Aires, Argentina
| | - Augusto Varese
- Instituto de Investigaciones Biomdicas en Retrovirus y SIDA, Universidad de Buenos Aires/CONICET, Buenos Aires, Argentina
| | - Jorge Geffner
- Instituto de Investigaciones Biomdicas en Retrovirus y SIDA, Universidad de Buenos Aires/CONICET, Buenos Aires, Argentina
| | - Natalia Bello
- Divisin Infectologa, Hospital de Clnicas Jos de San Martn, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Vanesa Fridman
- Divisin Infectologa, Hospital de Clnicas Jos de San Martn, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Daniel Stecher
- Divisin Infectologa, Hospital de Clnicas Jos de San Martn, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Ana Ceballos
- Instituto de Investigaciones Biomdicas en Retrovirus y SIDA, Universidad de Buenos Aires/CONICET, Buenos Aires, Argentina
| | - Federico Remes Lenicov
- Instituto de Investigaciones Biomdicas en Retrovirus y SIDA, Universidad de Buenos Aires/CONICET, Buenos Aires, Argentina
| |
Collapse
|
3
|
Reyes NS, Rodriguez PE, Ricarte C, Echegoyen N, Viegas M, Varese A, Ceballos A, Stryjewski ME, Echavarria M. Shedding of infectious SARS-CoV-2 in two asymptomatic children. Medicina (B Aires) 2023; 83:185-189. [PMID: 37094186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/26/2023] Open
Abstract
Asymptomatic infections with SARS-CoV-2 are associated with viral transmission and have a key role in the propagation of the pandemic. Understanding viral shedding during asymptomatic infections is critical. Unfortunately, data on asymptomatic SARS-CoV-2 infection in children is extremely limited. To determine the presence of viral viable shedding, we prospectively followed two healthy children of a family where both parents developed mild COVID-19 (April 2021). SARS-CoV-2 detection was made by RT-PCR and virus isolation by cell culture from saliva samples. Positive samples were sequenced to identify variants of SARS-CoV-2. Serum samples were evaluated to determine the presence of antibodies using a single enzyme-linked immunosorbent assay (ELISA, COVIDAR IgG). Both children were SARS-CoV-2 positive and asymptomatic. In addition, the virus grew in cell culture from saliva samples. Furthermore, one child showed viable SARS-CoV-2 for at least 17 days after the onset symptoms from his father. The recommended isolation period for asymptomatic contacts during the acquisition of data had been established for 10 days; however, this child remained with viable virus beyond that period. The positive samples from both children were consistent with B.1.1.28.1 lineage (Gamma). In both asymptomatic children, anti-Spike IgG was detected. Asymptomatic children may represent a source of infection that should not be underestimated during this pandemic.
Collapse
Affiliation(s)
- Noelia S Reyes
- Centro de Educación Médica e Investigaciones Clínicas (CEMIC), Buenos Aires. Argentina
| | - Pamela E Rodriguez
- Centro de Educación Médica e Investigaciones Clínicas (CEMIC), Buenos Aires. Argentina. E-mail:
| | - Carmen Ricarte
- Centro de Educación Médica e Investigaciones Clínicas (CEMIC), Buenos Aires. Argentina
| | - Natalia Echegoyen
- Centro de Educación Médica e Investigaciones Clínicas (CEMIC), Buenos Aires. Argentina
| | - Mariana Viegas
- Hospital de Niños Dr. Ricardo Gutiérrez, Buenos Aires. Argentina
| | - Augusto Varese
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Buenos Aires. Argentina
| | - Ana Ceballos
- 3Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Buenos Aires. Argentina
| | - Martín E Stryjewski
- Centro de Educación Médica e Investigaciones Clínicas (CEMIC), Buenos Aires. Argentina
| | - Marcela Echavarria
- Centro de Educación Médica e Investigaciones Clínicas (CEMIC), Buenos Aires. Argentina
| |
Collapse
|
4
|
Kundro M, Losso M, Macchia A, Pastor I, Alonso Serena M, Gestoso C, Moreno Macías L, Crupi F, Acosta M, Ivalo S, Ghioldi M, Bouzas M, Mammana L, Zapiola I, Mazzitelli I, Varese A, Geffner J, Biscayart C, Angeleri P, Lopez E, Gentile A, Ferrante D, de Quiros FGB. Safety and immunogenicity of heterologous COVID-19 vaccine regimens to deal with product shortage: A randomised clinical trial in an elderly population. Public Health Pract (Oxf) 2022; 4:100313. [PMID: 36090797 PMCID: PMC9444309 DOI: 10.1016/j.puhip.2022.100313] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2022] [Revised: 08/04/2022] [Accepted: 08/26/2022] [Indexed: 01/03/2023] Open
Abstract
Objectives In a context of COVID-19 vaccine shortages, this study sought to evaluate the safety and efficacy of receiving one dose of Gam-COVID-Vac rAd26 followed by a second COVID-19 vaccine dose of either Gam-COVID-Vac rAd5, ChAdOx1 nCoV-19 or BBIBP-CorV in a cohort of older adults. Study design Single-centre, randomised, open label, non-inferiority trial. Methods Adults aged ≥65 years who had received one dose of Gam-COVID-Vac rAd26 were randomised in a 1:1:1 ratio to receive a second-dose COVID-19 vaccination of either Gam-COVID-Vac rAd5, ChAdOx1 nCoV-19 or BBIBP-CorV. The primary outcome was the assessment of the humoral immune response to vaccination (i.e. antibody titres of SARS-CoV-2 spike protein at 28 days after second-dose vaccination). In addition, neutralising antibody titres at day 28 for the three schedules were measured. Results Of 85 participants who were enrolled in the study between 26 and July 30, 2021, 31 individuals were randomised to receive Gam-COVID-Vac rAd5, 27 to ChAdOx1 nCoV-19 and 27 to BBIBP-CorV. The mean age of participants was 68.2 years (SD 2.9) and 49 (57.6%) were female. Participants who received Gam-COVID-Vac rAd5 and ChAdOx1 nCoV1-19 showed significantly increased anti-S titres at 28 days after second-dose vaccination, but this magnitude of difference was not observed for those who received BBIBP-CorV. The ratio between the geometric mean at day 28 and baseline within each group was 11.8 (6.98-19.89) among patients assigned to Gam-COVID-Vac rAd26/rAd5, 4.81 (2.14-10.81) for the rAd26/ChAdOx1 nCoV-19 group and 1.53 (0.74-3.20) for the rAd26/BBIBP-CorV group. All of the schedules were shown to be safe. Conclusions The findings in this study contribute to the scarce information published on the safety and immunogenicity of Gam-COVID-Vac heterologous regimens and will help the development of guidelines and vaccine programme management.
Collapse
Affiliation(s)
- M.A. Kundro
- Área de Investigación en Enfermedades Emergentes, Hospital General de Agudos “J.M. Ramos Mejía”, Ciudad Autónoma de Buenos Aires, Argentina,Corresponding author. Área de Investigación en Enfermedades Emergentes Departamento de Medicina Hospital J.M. Ramos Mejía Urquiza 609.Buenos Aires. Argentina.
| | - M.H. Losso
- Área de Investigación en Enfermedades Emergentes, Hospital General de Agudos “J.M. Ramos Mejía”, Ciudad Autónoma de Buenos Aires, Argentina
| | - A. Macchia
- Ministerio de Salud del Gobierno de la Ciudad Autónoma de Buenos Aires, Argentina
| | - I. Pastor
- Área de Investigación en Enfermedades Emergentes, Hospital General de Agudos “J.M. Ramos Mejía”, Ciudad Autónoma de Buenos Aires, Argentina
| | - M. Alonso Serena
- Área de Investigación en Enfermedades Emergentes, Hospital General de Agudos “J.M. Ramos Mejía”, Ciudad Autónoma de Buenos Aires, Argentina
| | - C. Gestoso
- Área de Investigación en Enfermedades Emergentes, Hospital General de Agudos “J.M. Ramos Mejía”, Ciudad Autónoma de Buenos Aires, Argentina
| | - L. Moreno Macías
- Área de Investigación en Enfermedades Emergentes, Hospital General de Agudos “J.M. Ramos Mejía”, Ciudad Autónoma de Buenos Aires, Argentina
| | - F. Crupi
- Área de Investigación en Enfermedades Emergentes, Hospital General de Agudos “J.M. Ramos Mejía”, Ciudad Autónoma de Buenos Aires, Argentina
| | - M.C. Acosta
- Área de Investigación en Enfermedades Emergentes, Hospital General de Agudos “J.M. Ramos Mejía”, Ciudad Autónoma de Buenos Aires, Argentina
| | - S. Ivalo
- Área de Investigación en Enfermedades Emergentes, Hospital General de Agudos “J.M. Ramos Mejía”, Ciudad Autónoma de Buenos Aires, Argentina
| | - M. Ghioldi
- Área de Investigación en Enfermedades Emergentes, Hospital General de Agudos “J.M. Ramos Mejía”, Ciudad Autónoma de Buenos Aires, Argentina
| | - M.B. Bouzas
- Unidad de Virología, División Análisis Clínicos, Hospital de Infecciosas “Francisco J. Muñiz", Ciudad Autónoma de Buenos Aires, Argentina
| | - L. Mammana
- Unidad de Virología, División Análisis Clínicos, Hospital de Infecciosas “Francisco J. Muñiz", Ciudad Autónoma de Buenos Aires, Argentina
| | - I. Zapiola
- Unidad de Virología, División Análisis Clínicos, Hospital de Infecciosas “Francisco J. Muñiz", Ciudad Autónoma de Buenos Aires, Argentina
| | - I. Mazzitelli
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, Universidad de Buenos Aires, Argentina
| | - A. Varese
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, Universidad de Buenos Aires, Argentina
| | - J. Geffner
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, Universidad de Buenos Aires, Argentina
| | - C. Biscayart
- Subsecretaría de Planificación Sanitaria, Ministerio de Salud de la Ciudad de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina
| | - P. Angeleri
- Subsecretaría de Planificación Sanitaria, Ministerio de Salud de la Ciudad de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina
| | - E. Lopez
- Departamento de Medicina, Hospital de Niños “Ricardo Gutiérrez”, Ciudad Autónoma de Buenos Aires, Argentina
| | - A. Gentile
- Departamento de Epidemiología, Hospital de Niños “Ricardo Gutiérrez”, Ciudad Autónoma de Buenos Aires, Argentina
| | - D. Ferrante
- Ministerio de Salud del Gobierno de la Ciudad Autónoma de Buenos Aires, Argentina
| | | |
Collapse
|
5
|
Seery V, Raiden S, Russo C, Borda M, Herrera L, Uranga M, Varese A, Marcó Del Pont M, Chirino C, Erramuspe C, Álvarez LS, Lenoir M, Morales LD, Davenport C, Alarcón Flores A, Huespe Auchter S, Ruiz Y, Monsalvo L, Sastoque L, Gavazzi M, Mazzitelli I, Di Diego F, Longueira Y, Mazzitelli B, Sananez I, De Carli N, Biglione MM, Gómez Penedo JM, Ceballos A, Laufer N, Ferrero F, Geffner J, Arruvito L. Antibody response against SARS-CoV-2 variants of concern in children infected with pre-Omicron variants: An observational cohort study. EBioMedicine 2022; 83:104230. [PMID: 35988465 PMCID: PMC9387350 DOI: 10.1016/j.ebiom.2022.104230] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2022] [Revised: 07/30/2022] [Accepted: 08/02/2022] [Indexed: 12/27/2022] Open
Abstract
Background Despite that pediatric COVID-19 is usually asymptomatic or mild, SARS-CoV-2 infection typically results in the development of an antibody response. Contradictory observations have been reported when the antibody response of children and adults were compared in terms of strength, specificity and perdurability. Methods This observational study includes three cohorts infected with SARS-CoV-2 between March 2020-July 2021: unvaccinated infected children (n=115), unvaccinated infected adults (n=62), and vaccinated infected children (n=76). Plasma anti-spike IgG antibodies and neutralising activity against Wuhan, Delta and Omicron variants after 7-17 months post-infection were analysed. Findings More than 95% of unvaccinated infected children and adults remained seropositive when evaluated at 382-491 and 386-420 days after infection, respectively. Anti-spike IgG titers and plasma neutralising activity against Wuhan, Delta and Omicron variants were higher in children compared to adults. No differences were found when unvaccinated infected children were stratified by age, gender or presence/absence of symptoms in the acute phase of SARS-CoV-2 infection, but a slight decrease in the antibody response was observed in those with comorbidities. Vaccination of previously infected children with two doses of the inactivated BBIBP-CorV or the mRNA vaccines, BNT162b2 and/or mRNA-1273, further increased anti-spike IgG titers and neutralising activity against Wuhan, Delta and Omicron variants. Interpretation Unvaccinated infected children mount a more potent and sustained antibody response compared with adults, which is significantly increased after vaccination. Further studies including not only the analysis of the immune response but also the effectiveness to prevent reinfections by the different Omicron lineages are required to optimise vaccination strategy in children. Funding National Agency for Scientific and Technological Promotion from Argentina (PICTO-COVID-SECUELAS-00007 and PMO-BID-PICT2018-2548).
Collapse
Affiliation(s)
- Vanesa Seery
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS). Facultad de Medicina. UBA-CONICET, Paraguay 2155, C1121ABG Caba, Argentina
| | - Silvina Raiden
- Hospital General de Niños Pedro de Elizalde, Av. Montes de Oca 40, C1270 CABA, Argentina
| | - Constanza Russo
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS). Facultad de Medicina. UBA-CONICET, Paraguay 2155, C1121ABG Caba, Argentina
| | - Mauricio Borda
- Hospital Pediátrico Juan Pablo II, Av. Artigas 1435, W3400 Corrientes, Argentina
| | - Largión Herrera
- Hospital Dr. Salvador Mazza, Sta. Josefa Rosello 356, H3540 Chaco, Argentina
| | - Macarena Uranga
- Hospital Universitario Austral, Av. Juan Domingo Perón 1500, B1629 Buenos Aires, Argentina
| | - Augusto Varese
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS). Facultad de Medicina. UBA-CONICET, Paraguay 2155, C1121ABG Caba, Argentina
| | - María Marcó Del Pont
- Hospital Universitario Austral, Av. Juan Domingo Perón 1500, B1629 Buenos Aires, Argentina
| | - Carina Chirino
- Policlínico Regional Juan Domingo Perón, Maipú 450, D5732 San Luis, Argentina
| | - Constanza Erramuspe
- Policlínico Regional Juan Domingo Perón, Maipú 450, D5732 San Luis, Argentina
| | - Laura Silvana Álvarez
- Hospital Universitario Austral, Av. Juan Domingo Perón 1500, B1629 Buenos Aires, Argentina
| | - Melisa Lenoir
- Hospital Universitario Austral, Av. Juan Domingo Perón 1500, B1629 Buenos Aires, Argentina
| | | | - Carolina Davenport
- Hospital General de Niños Pedro de Elizalde, Av. Montes de Oca 40, C1270 CABA, Argentina
| | | | | | - Yanina Ruiz
- Hospital Dr. Salvador Mazza, Sta. Josefa Rosello 356, H3540 Chaco, Argentina
| | - Liliana Monsalvo
- Hospital Dr. Salvador Mazza, Sta. Josefa Rosello 356, H3540 Chaco, Argentina
| | - Laura Sastoque
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS). Facultad de Medicina. UBA-CONICET, Paraguay 2155, C1121ABG Caba, Argentina
| | - Magalí Gavazzi
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS). Facultad de Medicina. UBA-CONICET, Paraguay 2155, C1121ABG Caba, Argentina
| | - Ignacio Mazzitelli
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS). Facultad de Medicina. UBA-CONICET, Paraguay 2155, C1121ABG Caba, Argentina
| | - Facundo Di Diego
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS). Facultad de Medicina. UBA-CONICET, Paraguay 2155, C1121ABG Caba, Argentina
| | - Yesica Longueira
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS). Facultad de Medicina. UBA-CONICET, Paraguay 2155, C1121ABG Caba, Argentina
| | - Bianca Mazzitelli
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS). Facultad de Medicina. UBA-CONICET, Paraguay 2155, C1121ABG Caba, Argentina
| | - Inés Sananez
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS). Facultad de Medicina. UBA-CONICET, Paraguay 2155, C1121ABG Caba, Argentina
| | - Norberto De Carli
- Clínica del Niño de Quilmes, Av. Lamadrid 444, B1878 Buenos Aires, Argentina
| | - Mirna Marcela Biglione
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS). Facultad de Medicina. UBA-CONICET, Paraguay 2155, C1121ABG Caba, Argentina
| | | | - Ana Ceballos
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS). Facultad de Medicina. UBA-CONICET, Paraguay 2155, C1121ABG Caba, Argentina
| | - Natalia Laufer
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS). Facultad de Medicina. UBA-CONICET, Paraguay 2155, C1121ABG Caba, Argentina
| | - Fernando Ferrero
- Hospital General de Niños Pedro de Elizalde, Av. Montes de Oca 40, C1270 CABA, Argentina
| | - Jorge Geffner
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS). Facultad de Medicina. UBA-CONICET, Paraguay 2155, C1121ABG Caba, Argentina
| | - Lourdes Arruvito
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS). Facultad de Medicina. UBA-CONICET, Paraguay 2155, C1121ABG Caba, Argentina.
| |
Collapse
|
6
|
Rouco SO, Rodriguez PE, Miglietta EA, Rall P, Ledesma MMGL, Varese A, Pascuale CA, Ojeda DS, Mazzitelli B, Sanchez L, Ceballos A, Perez E, Geffner J, Miragaya Y, Rossi AH, Gamarnik AV. Heterologous booster response after inactivated virus BBIBP-CorV vaccination in older people. Lancet Infect Dis 2022; 22:1118-1119. [PMID: 35777383 PMCID: PMC9239573 DOI: 10.1016/s1473-3099(22)00427-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/16/2022] [Revised: 06/01/2022] [Accepted: 06/09/2022] [Indexed: 12/31/2022]
Affiliation(s)
| | | | | | - Pablo Rall
- Instituto Nacional de Servicios Sociales para Jubilados y Pensionados, Provincia de Buenos Aires, Argentina
| | | | - Augusto Varese
- Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Carla A Pascuale
- Fundación Instituto Leloir-CONICET, Buenos Aires 1405, Argentina
| | - Diego S Ojeda
- Fundación Instituto Leloir-CONICET, Buenos Aires 1405, Argentina
| | - Bianca Mazzitelli
- Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Lautaro Sanchez
- Fundación Instituto Leloir-CONICET, Buenos Aires 1405, Argentina
| | - Ana Ceballos
- Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Eduardo Perez
- Instituto Nacional de Servicios Sociales para Jubilados y Pensionados, Provincia de Buenos Aires, Argentina
| | - Jorge Geffner
- Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Yanina Miragaya
- Instituto Nacional de Servicios Sociales para Jubilados y Pensionados, Provincia de Buenos Aires, Argentina
| | - Andrés H Rossi
- Fundación Instituto Leloir-CONICET, Buenos Aires 1405, Argentina
| | | |
Collapse
|
7
|
Varese A, Mazzitelli B, Díaz FE, Kjolhede MV, Ojeda D, Vellicce A, Arto P, Cicero C, Pascowski M, Figueras L, Broese B, Dávila R, Zarlenga R, Rivelli F, Verruno C, Silenzi V, Beltrán I, Gamarnik A, Ceballos A, Zala C, Badolati A, Geffner J. Omicron breakthrough infection after heterologous prime-boost vaccination induces a vigorous antibody response. J Infect Dis 2022; 226:1717-1720. [PMID: 35723970 PMCID: PMC9384299 DOI: 10.1093/infdis/jiac250] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2022] [Accepted: 06/17/2022] [Indexed: 11/13/2022] Open
Abstract
Infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant is usually asymptomatic or mild and appears to be poorly immunogenic at least in unvaccinated individuals. Here, we found that health care workers vaccinated with 2 doses of Sputnik V and a booster dose of ChAdOx1 mount a vigorous neutralizing-antibody response after Omicron breakthrough infection.
Collapse
Affiliation(s)
- Augusto Varese
- Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina
| | - Bianca Mazzitelli
- Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina
| | - Fernando Erra Díaz
- Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina
| | - María Victoria Kjolhede
- Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina
| | - Diego Ojeda
- Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina
| | | | - Penélope Arto
- Hospital de Clínicas "José de San Martín", Buenos Aires, Argentina
| | - Carla Cicero
- Hospital de Clínicas "José de San Martín", Buenos Aires, Argentina
| | | | - Laura Figueras
- Hospital Central de San Isidro "Melchor A. Posse", Buenos Aires, Argentina
| | - Bárbara Broese
- Hospital Central de San Isidro "Melchor A. Posse", Buenos Aires, Argentina
| | - Rosa Dávila
- Hospital de Villa Mercedes "Juan Domingo Perón", San Luis, Argentina
| | - Rocío Zarlenga
- Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina
| | - Federico Rivelli
- Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina
| | - Camila Verruno
- Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina
| | - Valeria Silenzi
- Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina
| | - Ivana Beltrán
- Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina
| | | | - Ana Ceballos
- Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina
| | - Carlos Zala
- Hospital Central de San Isidro "Melchor A. Posse", Buenos Aires, Argentina
| | | | - Jorge Geffner
- Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina
| |
Collapse
|
8
|
Macchia A, Ferrante D, Bouzas MB, Angeleri P, Biscayart C, Geffner J, Mammana L, Zapiola I, López EL, Gentile A, Varese A, Mazzitelli I, García FDD, Sharff D, Lucconi V, Sujansky P, Mariani J, de Quirós FGB. Immunogenicity induced by the use of alternative vaccine platforms to deal with vaccine shortages in a low- to middle-income country: Results of two randomized clinical trials. Lancet Reg Health Am 2022; 9:100196. [PMID: 35128512 PMCID: PMC8808427 DOI: 10.1016/j.lana.2022.100196] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background Shortages of component two of Sputnik V vaccine (rAd5) are delaying the possibility of achieving full immunisation. The immunogenic response associated with the use of alternative schemes to complete the scheme was not explored. Methods We did two non-inferiority randomized clinical trials with outcomes measures blinded to investigators on adults aged 21–65 years, vaccinated with a single dose of rAd26 ≥ 30 days before screening and no history of SARS-CoV-2. Participants were assigned (1:1:1:1:1) to receive either rAd5; ChAdOx1; rAd26; mRNA-1273 or BBIBP-CorV. The primary endpoint was the geometric mean ratio (GMR) of SARS-CoV-2 anti-spike IgG concentration at 28 days after the second dose, when comparing rAd26/rAd5 with rAd26/ChAdOx1, rAd26/rAd26, rAd26/mRNAmRNA-1273 and rAd26/BBIBP-CorV. Serum neutralizing capacity was evaluated using wild type SARS-CoV-2 reference strain 2019 B.1. The safety outcome was 28-day rate of serious adverse. The primary analysis included all participants who received ≥ 1 dose. The studies were registered with NCT04962906 and NCT05027672. Both trials were conducted in Buenos Aires, Argentina. Findings Between July 6 and August 3, 2021, 540 individuals (age 56·7 [SD 7·3]; 243 (45%) women) were randomly assigned to received rAd5 (n=150); ChAdOx1 (n=150); rAd26 (N=87); mRNAmRNA-1273 (n=87) or BBIBP-CorV (n=65). 524 participants completed the study. As compared with rAd26/rAd5 (1·00), the GMR (95%CI) at day 28 was 0·65 (0·51–0·84) among those who received ChAdOx1; 0·47 (0·34–0·66) in rAd5; 3·53 (2·68–4·65) in mRNA-1273 and 0·23 (0·16–0·33) in BBIBP-CorV. The geometric mean (IU/ml) from baseline to day 28 within each group increased significantly with ChAdOx1 (4·08 (3·07–5·43)); rAd26 (2·69 (1·76–4·11)); mRNA-1273 (21·98 (15·45–31·08)) but not in BBIBP-CorV (1·22 (0·80–1·87)). Interpretation Except for mRNA-1273 which proved superior, in all other alternatives non-inferiority was rejected. Antibody concentration increased in all non-replicating viral vector and RNA platforms. Funding The trials were supported (including funding, material support in the form of vaccines and testing supplies) by the Buenos Aires City Government.
Collapse
Affiliation(s)
- Alejandro Macchia
- Subsecretaría de Planificación Sanitaria, Ministerio de Salud de la Ciudad de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina
| | - Daniel Ferrante
- Subsecretaría de Planificación Sanitaria, Ministerio de Salud de la Ciudad de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina
| | - María Belén Bouzas
- División Análisis Clínicos, Hospital "Francisco J. Muñiz", Ciudad Autónoma de Buenos Aires, Argentina
| | - Patricia Angeleri
- Subsecretaría de Planificación Sanitaria, Ministerio de Salud de la Ciudad de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina
| | - Cristián Biscayart
- Subsecretaría de Planificación Sanitaria, Ministerio de Salud de la Ciudad de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina
| | - Jorge Geffner
- Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA, Buenos Aires, Argentina
| | - Lilia Mammana
- Unidad de Virología, Hospital "Francisco J. Muñiz", Ciudad Autónoma de Buenos Aires, Argentina
| | - Inés Zapiola
- Unidad de Virología, Hospital "Francisco J. Muñiz", Ciudad Autónoma de Buenos Aires, Argentina
| | - Eduardo Luis López
- Hospital de Niños Dr. Ricardo Gutiérrez, Departamento de Medicina, Programa de Enfermedades Infecciosas, Ciudad Autónoma de Buenos Aires, Argentina
| | - Angela Gentile
- Hospital de Niños Dr. Ricardo Gutiérrez, Departamento de Epidemiología, Ciudad Autónoma de Buenos Aires, Argentina
| | - Augusto Varese
- Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA, Buenos Aires, Argentina
| | - Ignacio Mazzitelli
- Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA, Buenos Aires, Argentina
| | - Facundo Di Diego García
- Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA, Buenos Aires, Argentina
| | - Deborah Sharff
- Subsecretaría de Planificación Sanitaria, Ministerio de Salud de la Ciudad de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina
| | - Verónica Lucconi
- Subsecretaría de Planificación Sanitaria, Ministerio de Salud de la Ciudad de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina
| | - Paula Sujansky
- Subsecretaría de Planificación Sanitaria, Ministerio de Salud de la Ciudad de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina
| | - Javier Mariani
- Subsecretaría de Planificación Sanitaria, Ministerio de Salud de la Ciudad de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina
| | | |
Collapse
|
9
|
Coria LM, Saposnik LM, Pueblas Castro C, Castro EF, Bruno LA, Stone WB, Pérez PS, Darriba ML, Chemes LB, Alcain J, Mazzitelli I, Varese A, Salvatori M, Auguste AJ, Álvarez DE, Pasquevich KA, Cassataro J. A Novel Bacterial Protease Inhibitor Adjuvant in RBD-Based COVID-19 Vaccine Formulations Containing Alum Increases Neutralizing Antibodies, Specific Germinal Center B Cells and Confers Protection Against SARS-CoV-2 Infection in Mice. Front Immunol 2022; 13:844837. [PMID: 35296091 PMCID: PMC8919065 DOI: 10.3389/fimmu.2022.844837] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2021] [Accepted: 02/01/2022] [Indexed: 01/18/2023] Open
Abstract
In this work, we evaluated recombinant receptor binding domain (RBD)-based vaccine formulation prototypes with potential for further clinical development. We assessed different formulations containing RBD plus alum, AddaS03, AddaVax, or the combination of alum and U-Omp19: a novel Brucella spp. protease inhibitor vaccine adjuvant. Results show that the vaccine formulation composed of U-Omp19 and alum as adjuvants has a better performance: it significantly increased mucosal and systemic neutralizing antibodies in comparison to antigen plus alum, AddaVax, or AddaS03. Antibodies induced with the formulation containing U-Omp19 and alum not only increased their neutralization capacity against the ancestral virus but also cross-neutralized alpha, lambda, and gamma variants with similar potency. Furthermore, the addition of U-Omp19 to alum vaccine formulation increased the frequency of RBD-specific geminal center B cells and plasmablasts. Additionally, U-Omp19+alum formulation induced RBD-specific Th1 and CD8+ T-cell responses in spleens and lungs. Finally, this vaccine formulation conferred protection against an intranasal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) challenge of K18-hACE2 mice.
Collapse
Affiliation(s)
- Lorena M. Coria
- Instituto de Investigaciones Biotecnológicas Dr. Rodolfo A. Ugalde, Universidad Nacional de San Martín, Consejo Nacional de Investigaciones Científicas y Técnicas (UNSAM-CONICET), San Martín, Argentina
| | - Lucas M. Saposnik
- Instituto de Investigaciones Biotecnológicas Dr. Rodolfo A. Ugalde, Universidad Nacional de San Martín, Consejo Nacional de Investigaciones Científicas y Técnicas (UNSAM-CONICET), San Martín, Argentina
| | - Celeste Pueblas Castro
- Instituto de Investigaciones Biotecnológicas Dr. Rodolfo A. Ugalde, Universidad Nacional de San Martín, Consejo Nacional de Investigaciones Científicas y Técnicas (UNSAM-CONICET), San Martín, Argentina
| | - Eliana F. Castro
- Instituto de Investigaciones Biotecnológicas Dr. Rodolfo A. Ugalde, Universidad Nacional de San Martín, Consejo Nacional de Investigaciones Científicas y Técnicas (UNSAM-CONICET), San Martín, Argentina
- Instituto de Virología e Innovaciones Tecnológicas (IVIT), Centro de Investigaciones en Ciencias Veterinarias y Agronómicas (CICVyA), Instituto Nacional de Tecnología Agropecuaria (INTA)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - Laura A. Bruno
- Instituto de Investigaciones Biotecnológicas Dr. Rodolfo A. Ugalde, Universidad Nacional de San Martín, Consejo Nacional de Investigaciones Científicas y Técnicas (UNSAM-CONICET), San Martín, Argentina
| | - William B. Stone
- Department of Entomology, College of Agriculture and Life Sciences, Fralin Life Science Institute, Virginia Polytechnic Institute and State University, Blacksburg, VA, United States
| | - Paula S. Pérez
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS, Universidad de Buenos Aires-CONICET), Buenos Aires, Argentina
| | - Maria Laura Darriba
- Instituto de Investigaciones Biotecnológicas Dr. Rodolfo A. Ugalde, Universidad Nacional de San Martín, Consejo Nacional de Investigaciones Científicas y Técnicas (UNSAM-CONICET), San Martín, Argentina
| | - Lucia B. Chemes
- Instituto de Investigaciones Biotecnológicas Dr. Rodolfo A. Ugalde, Universidad Nacional de San Martín, Consejo Nacional de Investigaciones Científicas y Técnicas (UNSAM-CONICET), San Martín, Argentina
| | - Julieta Alcain
- Instituto de Investigaciones Biotecnológicas Dr. Rodolfo A. Ugalde, Universidad Nacional de San Martín, Consejo Nacional de Investigaciones Científicas y Técnicas (UNSAM-CONICET), San Martín, Argentina
| | - Ignacio Mazzitelli
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS, Universidad de Buenos Aires-CONICET), Buenos Aires, Argentina
| | - Augusto Varese
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS, Universidad de Buenos Aires-CONICET), Buenos Aires, Argentina
| | - Melina Salvatori
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS, Universidad de Buenos Aires-CONICET), Buenos Aires, Argentina
| | - Albert J. Auguste
- Department of Entomology, College of Agriculture and Life Sciences, Fralin Life Science Institute, Virginia Polytechnic Institute and State University, Blacksburg, VA, United States
- Center for Emerging, Zoonotic, and Arthropod-borne Pathogens, Virginia Polytechnic Institute and State University, Blacksburg, VA, United States
| | - Diego E. Álvarez
- Instituto de Investigaciones Biotecnológicas Dr. Rodolfo A. Ugalde, Universidad Nacional de San Martín, Consejo Nacional de Investigaciones Científicas y Técnicas (UNSAM-CONICET), San Martín, Argentina
| | - Karina A. Pasquevich
- Instituto de Investigaciones Biotecnológicas Dr. Rodolfo A. Ugalde, Universidad Nacional de San Martín, Consejo Nacional de Investigaciones Científicas y Técnicas (UNSAM-CONICET), San Martín, Argentina
- *Correspondence: Karina A. Pasquevich, ; Juliana Cassataro,
| | - Juliana Cassataro
- Instituto de Investigaciones Biotecnológicas Dr. Rodolfo A. Ugalde, Universidad Nacional de San Martín, Consejo Nacional de Investigaciones Científicas y Técnicas (UNSAM-CONICET), San Martín, Argentina
- *Correspondence: Karina A. Pasquevich, ; Juliana Cassataro,
| |
Collapse
|
10
|
Varese A, Nakawesi J, Farias A, Kirsebom FCM, Paulsen M, Nuriev R, Johansson C. Type I interferons and MAVS signaling are necessary for tissue resident memory CD8+ T cell responses to RSV infection. PLoS Pathog 2022; 18:e1010272. [PMID: 35108347 PMCID: PMC8843175 DOI: 10.1371/journal.ppat.1010272] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2021] [Revised: 02/14/2022] [Accepted: 01/12/2022] [Indexed: 01/15/2023] Open
Abstract
Respiratory syncytial virus (RSV) can cause bronchiolitis and viral pneumonia in young children and the elderly. Lack of vaccines and recurrence of RSV infection indicate the difficulty in eliciting protective memory immune responses. Tissue resident memory T cells (TRM) can confer protection from pathogen re-infection and, in human experimental RSV infection, the presence of lung CD8+ TRM cells correlates with a better outcome. However, the requirements for generating and maintaining lung TRM cells during RSV infection are not fully understood. Here, we use mouse models to assess the impact of innate immune response determinants in the generation and subsequent expansion of the TRM cell pool during RSV infection. We show that CD8+ TRM cells expand independently from systemic CD8+ T cells after RSV re-infection. Re-infected MAVS and MyD88/TRIF deficient mice, lacking key components involved in innate immune recognition of RSV and induction of type I interferons (IFN-α/β), display impaired expansion of CD8+ TRM cells and reduction in antigen specific production of granzyme B and IFN-γ. IFN-α treatment of MAVS deficient mice during primary RSV infection restored TRM cell expansion upon re-challenge but failed to recover TRM cell functionality. Our data reveal how innate immunity, including the axis controlling type I IFN induction, instructs and regulates CD8+ TRM cell responses to RSV infection, suggesting possible mechanisms for therapeutic intervention.
Collapse
Affiliation(s)
- Augusto Varese
- Respiratory Infections Section, St Mary’s campus, National Heart and Lung Institute, Imperial College London, London, United Kingdom
| | - Joy Nakawesi
- Respiratory Infections Section, St Mary’s campus, National Heart and Lung Institute, Imperial College London, London, United Kingdom
| | - Ana Farias
- Respiratory Infections Section, St Mary’s campus, National Heart and Lung Institute, Imperial College London, London, United Kingdom
| | - Freja C. M. Kirsebom
- Respiratory Infections Section, St Mary’s campus, National Heart and Lung Institute, Imperial College London, London, United Kingdom
| | - Michelle Paulsen
- Respiratory Infections Section, St Mary’s campus, National Heart and Lung Institute, Imperial College London, London, United Kingdom
| | - Rinat Nuriev
- Respiratory Infections Section, St Mary’s campus, National Heart and Lung Institute, Imperial College London, London, United Kingdom
| | - Cecilia Johansson
- Respiratory Infections Section, St Mary’s campus, National Heart and Lung Institute, Imperial College London, London, United Kingdom
| |
Collapse
|
11
|
Paletta A, Di Diego García F, Varese A, Erra Diaz F, García J, Cisneros JC, Ludueña G, Mazzitelli I, Pisarevsky A, Cabrerizo G, López Malizia Á, Rodriguez AG, Lista N, Longueira Y, Sabatté J, Geffner J, Remes Lenicov F, Ceballos A. Platelets modulate CD4 + T Cell function in Covid-19 Through A PD-L1 Dependent Mechanism. Br J Haematol 2022; 197:283-292. [PMID: 35076084 DOI: 10.1111/bjh.18062] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2021] [Revised: 01/13/2022] [Accepted: 01/13/2022] [Indexed: 11/29/2022]
Abstract
Severe COVID-19 is associated with a systemic inflammatory response and progressive CD4+ T cell lymphopenia and dysfunction. We evaluated whether platelets might contribute to CD4+ T cell dysfunction in COVID-19. We observed a high frequency of CD4+ T cell-platelet aggregates in COVID-19 inpatients that inversely correlated with lymphocyte counts. Platelets from COVID-19 inpatients but not from healthy donors (HD) inhibited the up-regulation of CD25 expression and TNF-α production by CD4+ T cells. In addition, IFN-γ production was increased by platelets from HD but not from COVID-19 inpatients. A high expression of PD-L1 was found in platelets from COVID-19 patients to be inversely correlated with IFN-γ production by activated CD4+ T cells co-cultured with platelets. We also found that a PD-L1 blocking antibody significantly restored platelet-ability to stimulate IFN-γ production by CD4+ T cells. Our study suggests that platelets might contribute to disease progression in COVID-19 not only by promoting thrombotic and inflammatory events, but also by affecting CD4+ T cells functionality.
Collapse
Affiliation(s)
- Ana Paletta
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires (UBA)-CONICET, Buenos Aires, Argentina
| | - Facundo Di Diego García
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires (UBA)-CONICET, Buenos Aires, Argentina
| | - Augusto Varese
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires (UBA)-CONICET, Buenos Aires, Argentina
| | - Fernando Erra Diaz
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires (UBA)-CONICET, Buenos Aires, Argentina
| | - Julián García
- División C, Hospital de Enfermedades Infecciosas Francisco Muñiz, Buenos Aires, Argentina
| | - Juan Carlos Cisneros
- Unidad de Terapia Intensiva, Hospital de Enfermedades Infecciosas Francisco Muñiz, Buenos Aires, Argentina
| | - Guillermina Ludueña
- Departamento de Medicina Interna, Hospital de Clínicas, Universidad de Buenos Aires, Argentina
| | - Ignacio Mazzitelli
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires (UBA)-CONICET, Buenos Aires, Argentina
| | - Andrea Pisarevsky
- Departamento de Medicina Interna, Hospital de Clínicas, Universidad de Buenos Aires, Argentina
| | - Gonzalo Cabrerizo
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires (UBA)-CONICET, Buenos Aires, Argentina
| | - Álvaro López Malizia
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires (UBA)-CONICET, Buenos Aires, Argentina
| | - Alejandra G Rodriguez
- Unidad de Terapia Intensiva, Hospital de Enfermedades Infecciosas Francisco Muñiz, Buenos Aires, Argentina
| | - Nicolás Lista
- Unidad de Terapia Intensiva, Hospital de Enfermedades Infecciosas Francisco Muñiz, Buenos Aires, Argentina
| | - Yesica Longueira
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires (UBA)-CONICET, Buenos Aires, Argentina
| | - Juan Sabatté
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires (UBA)-CONICET, Buenos Aires, Argentina
| | - Jorge Geffner
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires (UBA)-CONICET, Buenos Aires, Argentina
| | - Federico Remes Lenicov
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires (UBA)-CONICET, Buenos Aires, Argentina
| | - Ana Ceballos
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires (UBA)-CONICET, Buenos Aires, Argentina
| |
Collapse
|
12
|
González Viacava MB, Varese A, Mazzitelli I, Lanari L, Ávila L, García Vampa MJ, Geffner J, Cascone O, Dokmetjian JC, de Roodt AR, Fingermann M. Immune Maturation Effects on Viral Neutralization and Avidity of Hyperimmunized Equine Anti-SARS-CoV-2 Sera. Antibodies (Basel) 2022; 11:3. [PMID: 35076465 PMCID: PMC8788445 DOI: 10.3390/antib11010003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2021] [Revised: 08/19/2021] [Accepted: 09/09/2021] [Indexed: 01/19/2023] Open
Abstract
Mass-vaccination against COVID-19 is still a distant goal for most low-to-middle income countries. The experience gained through decades producing polyclonal immunotherapeutics (such as antivenoms) in many of those countries is being redirected to develop similar products able to neutralize SARS-CoV-2 infection. In this study we analyzed the biological activity (viral neutralization or NtAb) and immunochemical properties of hyperimmune horses' sera (HHS) obtained during initial immunization (I) and posterior re-immunization (R) cycles using the RBD domain of the SARS-CoV-2 spike protein as antigen. HHS at the end of the R cycle showed higher NtAb titers when compared to those after the I cycle (35,585 vs. 7000 mean NtAb, respectively). Moreover, this increase paralleled an increase in avidity (95.2% to 65.2% mean avidity units, respectively). The results presented herein are relevant for manufacturers of these therapeutic tools against COVID-19.
Collapse
Affiliation(s)
- Myriam Belén González Viacava
- Instituto Nacional de Producción de Biológicos (INPB), ANLIS “Dr. Carlos G. Malbrán”, Vélez Sársfield 563, Buenos Aires 1282, Argentina; (M.B.G.V.); (L.L.); (L.Á.); (M.J.G.V.); (O.C.); (J.C.D.); (A.R.d.R.)
| | - Augusto Varese
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires (UBA) and Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Paraguay 2155, 11th Floor, Buenos Aires 1113, Argentina; (A.V.); (I.M.); (J.G.)
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, Buenos Aires 1425, Argentina
| | - Ignacio Mazzitelli
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires (UBA) and Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Paraguay 2155, 11th Floor, Buenos Aires 1113, Argentina; (A.V.); (I.M.); (J.G.)
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, Buenos Aires 1425, Argentina
| | - Laura Lanari
- Instituto Nacional de Producción de Biológicos (INPB), ANLIS “Dr. Carlos G. Malbrán”, Vélez Sársfield 563, Buenos Aires 1282, Argentina; (M.B.G.V.); (L.L.); (L.Á.); (M.J.G.V.); (O.C.); (J.C.D.); (A.R.d.R.)
| | - Lucía Ávila
- Instituto Nacional de Producción de Biológicos (INPB), ANLIS “Dr. Carlos G. Malbrán”, Vélez Sársfield 563, Buenos Aires 1282, Argentina; (M.B.G.V.); (L.L.); (L.Á.); (M.J.G.V.); (O.C.); (J.C.D.); (A.R.d.R.)
| | - María Julia García Vampa
- Instituto Nacional de Producción de Biológicos (INPB), ANLIS “Dr. Carlos G. Malbrán”, Vélez Sársfield 563, Buenos Aires 1282, Argentina; (M.B.G.V.); (L.L.); (L.Á.); (M.J.G.V.); (O.C.); (J.C.D.); (A.R.d.R.)
| | - Jorge Geffner
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires (UBA) and Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Paraguay 2155, 11th Floor, Buenos Aires 1113, Argentina; (A.V.); (I.M.); (J.G.)
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, Buenos Aires 1425, Argentina
| | - Osvaldo Cascone
- Instituto Nacional de Producción de Biológicos (INPB), ANLIS “Dr. Carlos G. Malbrán”, Vélez Sársfield 563, Buenos Aires 1282, Argentina; (M.B.G.V.); (L.L.); (L.Á.); (M.J.G.V.); (O.C.); (J.C.D.); (A.R.d.R.)
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, Buenos Aires 1425, Argentina
- Instituto de Nanobiotecnología (NANOBIOTEC), Universidad de Buenos Aires (UBA) and Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Junín 956, Buenos Aires 1113, Argentina
| | - José Christian Dokmetjian
- Instituto Nacional de Producción de Biológicos (INPB), ANLIS “Dr. Carlos G. Malbrán”, Vélez Sársfield 563, Buenos Aires 1282, Argentina; (M.B.G.V.); (L.L.); (L.Á.); (M.J.G.V.); (O.C.); (J.C.D.); (A.R.d.R.)
| | - Adolfo Rafael de Roodt
- Instituto Nacional de Producción de Biológicos (INPB), ANLIS “Dr. Carlos G. Malbrán”, Vélez Sársfield 563, Buenos Aires 1282, Argentina; (M.B.G.V.); (L.L.); (L.Á.); (M.J.G.V.); (O.C.); (J.C.D.); (A.R.d.R.)
- Cátedra de Toxicología, Facultad de Medicina, Universidad de Buenos Aires, Paraguay 2155, Buenos Aires 1113, Argentina
| | - Matías Fingermann
- Instituto Nacional de Producción de Biológicos (INPB), ANLIS “Dr. Carlos G. Malbrán”, Vélez Sársfield 563, Buenos Aires 1282, Argentina; (M.B.G.V.); (L.L.); (L.Á.); (M.J.G.V.); (O.C.); (J.C.D.); (A.R.d.R.)
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, Buenos Aires 1425, Argentina
| |
Collapse
|
13
|
Varese A, Paletta A, Ceballos A, Palacios CA, Figueroa JM, Dugour AV. Iota-Carrageenan Prevents the Replication of SARS-CoV-2 in a Human Respiratory Epithelium Cell Line in vitro. Front Virol 2021. [DOI: 10.3389/fviro.2021.746824] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Iota-carrageenan is a sulfated polysaccharide extracted from red seaweeds, which, formulated into a nasal spray, has already been proven safe and effective in viral upper respiratory infections. In Calu-3, a human respiratory epithelium cell line, we explored the activity of a formula of iota-carrageenan and sodium chloride against SARS-CoV-2. In this study, the assayed formula, already approved as a nasal spray for human use, effectively inhibited SARS-CoV-2 infection, providing a more substantial reference for clinical studies or developments.
Collapse
|
14
|
Sananez I, Raiden SC, Algieri SC, Uranga M, Grisolía NA, Filippo D, De Carli N, Lalla SD, Cairoli H, Chiolo MJ, Meregalli CN, Cohen E, Mosquera G, Marcó Del Pont M, Giménez LI, Gregorio G, Sarli M, Alcalde AL, Davenport C, Bruera MJ, Simaz N, Pérez MF, Nivela V, Bayle C, Alvarez L, Revetria M, Tuccillo P, Agosta MT, Pérez H, Nova SV, Suárez P, Takata EM, García M, Lattner J, Rolón MJ, Coll P, Salvatori M, Piccardo C, Russo C, Varese A, Seery V, Holgado MP, Polo ML, Ceballos A, Nuñez M, Penedo JMG, Ferrero F, Geffner J, Arruvito L. A poor and delayed anti-SARS-CoV2 IgG response is associated to severe COVID-19 in children. EBioMedicine 2021; 72:103615. [PMID: 34649078 PMCID: PMC8502533 DOI: 10.1016/j.ebiom.2021.103615] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2021] [Revised: 09/10/2021] [Accepted: 09/21/2021] [Indexed: 12/15/2022] Open
Abstract
Background Most children and youth develop mild or asymptomatic disease during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, a very small number of patients suffer severe Coronavirus induced disease 2019 (COVID-19). The reasons underlying these different outcomes remain unknown. Methods We analyzed three different cohorts: children with acute infection (n=550), convalescent children (n=138), and MIS-C (multisystem inflammatory syndrome in children, n=42). IgG and IgM antibodies to the spike protein of SARS-CoV-2, serum-neutralizing activity, plasma cytokine levels, and the frequency of circulating Follicular T helper cells (cTfh) and plasmablasts were analyzed by conventional methods. Findings Fifty-eight percent of the children in the acute phase of infection had no detectable antibodies at the time of sampling while a seronegative status was found in 25% and 12% of convalescent and MIS-C children, respectively. When children in the acute phase of the infection were stratified according disease severity, we found that contrasting with the response of children with asymptomatic, mild and moderate disease, children with severe COVID-19 did not develop any detectable response. A defective antibody response was also observed in the convalescent cohort for children with severe disease at the time of admission. This poor antibody response was associated to both, a low frequency of cTfh and a high plasma concentration of inflammatory cytokines. Interpretation A weak and delayed kinetic of antibody response to SARS-CoV-2 together with a systemic pro-inflammatory profile characterize pediatric severe COVID-19. Because comorbidities are highly prevalent in children with severe COVID-19, further studies are needed to clarify their contribution in the weak antibody response observed in severe disease. Funding National Agency for Scientific and Technological Promotion from Argentina (IP-COVID-19-0277 and PMO-BID-PICT2018-2548).
Collapse
Affiliation(s)
- Inés Sananez
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA. Facultad de Medicina. UBA-CONICET. Paraguay 2155, C1121ABG CABA, Argentina
| | - Silvina C Raiden
- Departamento de Medicina, Hospital General de Niños Pedro de Elizalde. Av. Montes de Oca 40, C1270 CABA, Argentina
| | - Silvia C Algieri
- Servicio de Pediatría, Hospital Nacional Profesor Alejandro Posadas. Marconi Morón 386, B1684 Buenos Aires, Argentina
| | - Macarena Uranga
- Sector Infectología infantil, Departamento Materno Infantil, Hospital Universitario Austral. Av. Juan Domingo Perón 1500, B1629 Buenos Aires, Argentina
| | - Nicolás A Grisolía
- Departamento de Medicina, Hospital General de Niños Pedro de Elizalde. Av. Montes de Oca 40, C1270 CABA, Argentina
| | - Daniela Filippo
- Servicio de Pediatría, Hospital Municipal Diego Thompson. Avellaneda 33, B1650 Buenos Aires, Argentina
| | - Norberto De Carli
- Servicio de Pediatría, Clínica del Niño de Quilmes. Av. Lamadrid 444, B1878 Buenos Aires, Argentina
| | - Sandra Di Lalla
- Departamento de Consultorios Externos, Hospital General de Niños Pedro de Elizalde. Av. Montes de Oca 40, C1270 CABA, Argentina
| | - Héctor Cairoli
- Departamento de Medicina, Hospital General de Niños Pedro de Elizalde. Av. Montes de Oca 40, C1270 CABA, Argentina
| | - María J Chiolo
- Departamento de Cirugía, Hospital General de Niños Pedro de Elizalde. Av. Montes de Oca 40, C1270 CABA, Argentina
| | - Claudia N Meregalli
- Unidad de Terapia Intensiva Pediátrica, Departamento de Urgencias, Hospital General de Niños Pedro de Elizalde. Av. Montes de Oca 40, C1270 CABA, Argentina
| | - Emilia Cohen
- Servicio de Pediatría, Hospital HIGA Eva Perón. Av. Dr Ricardo Balbín 3200, B1650 Buenos Aires, Argentina
| | - Graciela Mosquera
- Servicio de Pediatría, Hospital HIGA Eva Perón. Av. Dr Ricardo Balbín 3200, B1650 Buenos Aires, Argentina
| | - María Marcó Del Pont
- Sector Infectología infantil, Departamento Materno Infantil, Hospital Universitario Austral. Av. Juan Domingo Perón 1500, B1629 Buenos Aires, Argentina
| | - Lorena I Giménez
- Servicio de Pediatría, Hospital Municipal Diego Thompson. Avellaneda 33, B1650 Buenos Aires, Argentina
| | - Gabriela Gregorio
- Servicio de Pediatría, Hospital Nacional Profesor Alejandro Posadas. Marconi Morón 386, B1684 Buenos Aires, Argentina
| | - Mariam Sarli
- Unidad de Terapia Intensiva Pediátrica, Hospital Nacional Profesor Alejandro Posadas. Marconi Morón 386, B1684 Buenos Aires, Argentina
| | - Ana L Alcalde
- Servicio de Pediatría, Hospital Nacional Profesor Alejandro Posadas. Marconi Morón 386, B1684 Buenos Aires, Argentina
| | - Carolina Davenport
- Departamento de Medicina, Hospital General de Niños Pedro de Elizalde. Av. Montes de Oca 40, C1270 CABA, Argentina
| | - María J Bruera
- Unidad de Terapia Intensiva Pediátrica, Hospital Nacional Profesor Alejandro Posadas. Marconi Morón 386, B1684 Buenos Aires, Argentina
| | - Nancy Simaz
- Servicio de Pediatría, Hospital Nacional Profesor Alejandro Posadas. Marconi Morón 386, B1684 Buenos Aires, Argentina
| | - Mariela F Pérez
- Servicio de Pediatría, Hospital Nacional Profesor Alejandro Posadas. Marconi Morón 386, B1684 Buenos Aires, Argentina
| | - Valeria Nivela
- Departamento de Emergencias Pediátrica, Hospital Nacional Profesor Alejandro Posadas. Marconi Morón 386, B1684 Buenos Aires, Argentina
| | - Carola Bayle
- Departamento de Emergencias Pediátrica, Hospital Nacional Profesor Alejandro Posadas. Marconi Morón 386, B1684 Buenos Aires, Argentina
| | - Laura Alvarez
- Departamento Laboratorio, Hospital Universitario Austral. Av. Juan Domingo Perón 1500, B1629 Buenos Aires, Argentina
| | - María Revetria
- Departamento Laboratorio, Hospital Universitario Austral. Av. Juan Domingo Perón 1500, B1629 Buenos Aires, Argentina
| | - Patricia Tuccillo
- Servicio de Pediatría, Hospital Naval Cirujano Mayor Dr. Pedro Mallo. Av. Patricias Argentinas 351, C1405 CABA, Argentina
| | - María T Agosta
- Servicio de Pediatría, Hospital Naval Cirujano Mayor Dr. Pedro Mallo. Av. Patricias Argentinas 351, C1405 CABA, Argentina
| | - Hernán Pérez
- Servicio de Pediatría, Hospital Naval Cirujano Mayor Dr. Pedro Mallo. Av. Patricias Argentinas 351, C1405 CABA, Argentina
| | - Susana Villa Nova
- Servicio de Pediatría, Hospital General de Agudos Dr. Juan A. Fernández. Av. Cerviño 3356, C1425 CABA, Argentina
| | - Patricia Suárez
- Servicio de Pediatría, Hospital General de Agudos Dr. Juan A. Fernández. Av. Cerviño 3356, C1425 CABA, Argentina
| | - Eugenia M Takata
- Servicio de Pediatría, Hospital General de Agudos Dr. Juan A. Fernández. Av. Cerviño 3356, C1425 CABA, Argentina
| | - Mariela García
- Servicio de Pediatría, Hospital General de Agudos Dr. Juan A. Fernández. Av. Cerviño 3356, C1425 CABA, Argentina
| | - Jorge Lattner
- Servicio de Infectología Pediátrica, Hospital Naval Cirujano Mayor Dr. Pedro Mallo. Av. Patricias Argentinas 351, C1405 CABA, Argentina
| | - María J Rolón
- División Infectología, Hospital General de Agudos Dr. Juan A. Fernández. Av. Cerviño 3356, C1425 CABA, Argentina
| | - Patricia Coll
- División Infectología, Hospital General de Agudos Dr. Juan A. Fernández. Av. Cerviño 3356, C1425 CABA, Argentina
| | - Melina Salvatori
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA. Facultad de Medicina. UBA-CONICET. Paraguay 2155, C1121ABG CABA, Argentina
| | - Claudio Piccardo
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA. Facultad de Medicina. UBA-CONICET. Paraguay 2155, C1121ABG CABA, Argentina
| | - Constanza Russo
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA. Facultad de Medicina. UBA-CONICET. Paraguay 2155, C1121ABG CABA, Argentina
| | - Augusto Varese
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA. Facultad de Medicina. UBA-CONICET. Paraguay 2155, C1121ABG CABA, Argentina
| | - Vanesa Seery
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA. Facultad de Medicina. UBA-CONICET. Paraguay 2155, C1121ABG CABA, Argentina
| | - María P Holgado
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA. Facultad de Medicina. UBA-CONICET. Paraguay 2155, C1121ABG CABA, Argentina
| | - María L Polo
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA. Facultad de Medicina. UBA-CONICET. Paraguay 2155, C1121ABG CABA, Argentina
| | - Ana Ceballos
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA. Facultad de Medicina. UBA-CONICET. Paraguay 2155, C1121ABG CABA, Argentina
| | - Myriam Nuñez
- Cátedra de Matemática. Facultad de Farmacia y Bioquímica. UBA. Junín 954, C1113 AAD CABA, Argentina
| | - Juan Martín Gómez Penedo
- Laboratorio de Análisis Estadísticos, Secretaría de Investigaciones. Facultad de Psicología. UBA- CONICET. Av. Hipólito Yrigoyen 3242, C1207 ABR CABA, Argentina
| | - Fernando Ferrero
- Departamento de Medicina, Hospital General de Niños Pedro de Elizalde. Av. Montes de Oca 40, C1270 CABA, Argentina
| | - Jorge Geffner
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA. Facultad de Medicina. UBA-CONICET. Paraguay 2155, C1121ABG CABA, Argentina
| | - Lourdes Arruvito
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA. Facultad de Medicina. UBA-CONICET. Paraguay 2155, C1121ABG CABA, Argentina.
| |
Collapse
|
15
|
Rossi AH, Ojeda DS, Varese A, Sanchez L, Gonzalez Lopez Ledesma MM, Mazzitelli I, Alvarez Juliá A, Oviedo Rouco S, Pallarés HM, Costa Navarro GS, Rasetto NB, Garcia CI, Wenker SD, Ramis LY, Bialer MG, de Leone MJ, Hernando CE, Sosa S, Bianchimano L, Rios AS, Treffinger Cienfuegos MS, Caramelo JJ, Longueira Y, Laufer N, Alvarez DE, Carradori J, Pedrozza D, Rima A, Echegoyen C, Ercole R, Gelpi P, Marchetti S, Zubieta M, Docena G, Kreplak N, Yanovsky M, Geffner J, Pifano M, Gamarnik AV. Sputnik V vaccine elicits seroconversion and neutralizing capacity to SARS-CoV-2 after a single dose. Cell Rep Med 2021; 2:100359. [PMID: 34308389 PMCID: PMC8266543 DOI: 10.1016/j.xcrm.2021.100359] [Citation(s) in RCA: 38] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/06/2021] [Revised: 06/22/2021] [Accepted: 07/05/2021] [Indexed: 10/28/2022]
Abstract
Massive vaccination offers great promise for halting the global COVID-19 pandemic. However, the limited supply and uneven vaccine distribution create an urgent need to optimize vaccination strategies. We evaluate SARS-CoV-2-specific antibody responses after Sputnik V vaccination of healthcare workers in Argentina, measuring IgG anti-spike titers and neutralizing capacity after one and two doses in a cohort of naive or previously infected volunteers. By 21 days after receiving the first dose of the vaccine, 94% of naive participants develop spike-specific IgG antibodies. A single Sputnik V dose elicits higher antibody levels and virus-neutralizing capacity in previously infected individuals than in naive ones receiving the full two-dose schedule. The high seroconversion rate after a single dose in naive participants suggests a benefit of delaying administration of the second dose to increase the number of people vaccinated. The data presented provide information for guiding public health decisions in light of the current global health emergency.
Collapse
Affiliation(s)
- Andres H Rossi
- Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
| | - Diego S Ojeda
- Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
| | - Augusto Varese
- Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina
| | - Lautaro Sanchez
- Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
| | | | - Ignacio Mazzitelli
- Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina
| | - Anabel Alvarez Juliá
- Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
| | - Santiago Oviedo Rouco
- Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
| | - Horacio M Pallarés
- Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
| | | | - Natali B Rasetto
- Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
| | - Corina I Garcia
- Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
| | - Shirley D Wenker
- Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
| | - Lila Y Ramis
- Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
| | - Magalí G Bialer
- Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
| | - Maria Jose de Leone
- Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
| | - C Esteban Hernando
- Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
| | - Santiago Sosa
- Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
| | - Luciana Bianchimano
- Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
| | - Antonella S Rios
- Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
| | | | - Julio J Caramelo
- Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
| | - Yesica Longueira
- Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina.,Biobanco de Enfermedades Infecciosas (INBIRS-UBA-CONICET), Caba, Argentina
| | - Natalia Laufer
- Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina.,Biobanco de Enfermedades Infecciosas (INBIRS-UBA-CONICET), Caba, Argentina
| | - Diego E Alvarez
- Instituto de Investigaciones Biotecnológicas, Univ. Nacional de San Martín-CONICET, Buenos Aires, Argentina
| | | | - Dariana Pedrozza
- Hospital Interzonal General de Agudos Dr Pedro Fiorito, Provincia de Buenos Aires, Argentina
| | - Alejandra Rima
- Hospital Interzonal General de Agudos Evita, Provincia de Buenos Aires, Argentina
| | - Cecilia Echegoyen
- Hospital Interzonal General de Agudos Prof. Dr. Rodolfo Rossi, Provincia de Buenos Aires, Argentina
| | - Regina Ercole
- Hospital Interzonal Especializado de Agudos y Crónicos San Juan de Dios, Provincia de Buenos Aires, Argentina
| | - Paula Gelpi
- Hospital Interzonal General de Agudos San Roque, Provincia de Buenos Aires, Argentina
| | - Susana Marchetti
- Hospital Interzonal General de Agudos San Martín, Provincia de Buenos Aires, Argentina
| | - Martín Zubieta
- Hospital de Alta Complejidad El Cruce "Nestor Kirchner," Provincia de Buenos Aires, Argentina
| | - Guillermo Docena
- Instituto de Estudios Inmunológicos y Fisiopatológicos, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, CONICET-CIC, La Plata, Argentina
| | | | - Marcelo Yanovsky
- Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
| | - Jorge Geffner
- Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina
| | - Marina Pifano
- Ministerio de Salud de Provincia de Buenos Aires, Argentina
| | - Andrea V Gamarnik
- Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
| |
Collapse
|
16
|
Varese A, Dantas E, Paletta A, Fitzgerald W, Di Diego García F, Cabrerizo G, Erra Diaz F, Defelipe LA, Pallares H, Dodes Traian M, Gamarnik A, Geffner J, Remes Lenicov F, Margolis L, Ceballos A. Extracellular acidosis enhances Zika virus infection both in human cells and ex-vivo tissue cultures from female reproductive tract. Emerg Microbes Infect 2021; 10:1169-1179. [PMID: 34013833 PMCID: PMC8205022 DOI: 10.1080/22221751.2021.1932606] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Zika virus (ZIKV) is a flavivirus transmitted by mosquitoes of the genus Aedes, but unlike other flaviviruses, ZIKV can be sexually transmitted by vaginal intercourse. The healthy vaginal pH ranges from 4.0 to 6.0, reaching values of 6.0-7.0 after semen deposition. Here, we report that low extracellular pH values (range 6.2-6.6) dramatically increase ZIKV infection on cell lines of different origin including some derived from the female genital tract and monocyte-derived macrophages. Furthermore, low pH significantly increased ZIKV infection of human ectocervix and endocervix cultured ex-vivo. Enhancement of infection by low pH was also observed using different ZIKV strains and distinct methods to evaluate viral infection, i.e. plaque assays, RT-PCR, flow cytometry, and fluorescence microscopy. Analysis of the mechanisms involved revealed that the enhancement of ZIKV infection induced by low pH was associated with increased binding of the viral particles to the heparan sulphate expressed on the target cell surface. Acidosis represents a critical but generally overlooked feature of the female genital tract, with major implications for sexual transmission diseases. Our results suggest that low vaginal pH might promote male-to-female transmission of ZIKV infection.
Collapse
Affiliation(s)
- A Varese
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires (UBA) and Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad de Buenos Aires, Argentina
| | - E Dantas
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires (UBA) and Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad de Buenos Aires, Argentina
| | - A Paletta
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires (UBA) and Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad de Buenos Aires, Argentina
| | - W Fitzgerald
- Section on Intercellular Interaction, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA
| | - F Di Diego García
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires (UBA) and Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad de Buenos Aires, Argentina
| | - G Cabrerizo
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires (UBA) and Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad de Buenos Aires, Argentina
| | - F Erra Diaz
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires (UBA) and Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad de Buenos Aires, Argentina
| | - L A Defelipe
- Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, IQUIBICEN-CONICET, Ciudad de Buenos Aires, Argentina
| | - H Pallares
- Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina
| | - M Dodes Traian
- Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, IQUIBICEN-CONICET, Ciudad de Buenos Aires, Argentina
| | - A Gamarnik
- Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina
| | - J Geffner
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires (UBA) and Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad de Buenos Aires, Argentina
| | - F Remes Lenicov
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires (UBA) and Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad de Buenos Aires, Argentina
| | - L Margolis
- Section on Intercellular Interaction, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA
| | - A Ceballos
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires (UBA) and Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad de Buenos Aires, Argentina
| |
Collapse
|
17
|
Paulsen M, Varese A, Pinpathomrat N, Kirsebom FCM, Paulsen M, Johansson C. MAVS Deficiency Is Associated With a Reduced T Cell Response Upon Secondary RSV Infection in Mice. Front Immunol 2020; 11:572747. [PMID: 33123150 PMCID: PMC7573121 DOI: 10.3389/fimmu.2020.572747] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2020] [Accepted: 09/16/2020] [Indexed: 11/17/2022] Open
Abstract
Infections with respiratory syncytial virus (RSV) occurs repeatedly throughout life because sustained, protective memory responses fail to develop. Why this occurs is not known. During RSV infection the recognition of the virus via the cytosolic RIG-I like receptors and signaling via the adaptor protein MAVS is crucial for mounting an innate immune response. However, if this signaling pathway is important for T cell responses during primary infection and during re-infection is not fully elucidated. We describe a second peak of pro-inflammatory mediators during the primary immune response to RSV that coincides with the arrival of T cells into the lung. This second peak of cytokines/chemokines is regulated differently than the early peak and is largely independent of signaling via MAVS. This was concurrent with Mavs−/− mice mounting a strong T cell response to primary RSV infection, with robust IFN-γ; and Granzyme B production. However, after RSV re-infection, Mavs−/− mice showed fewer CD4+ and CD8+ short term memory T cells and their capacity to produce IFN-γ; and Granzyme B, was decreased. In sum, cytosolic recognition of RSV is important not only for initiating innate anti-viral responses but also for generating or maintaining efficient, short term T cell memory responses.
Collapse
Affiliation(s)
- Michelle Paulsen
- Respiratory Infections Section, St Mary's Campus, National Heart and Lung Institute, Imperial College London, London, United Kingdom
| | - Augusto Varese
- Respiratory Infections Section, St Mary's Campus, National Heart and Lung Institute, Imperial College London, London, United Kingdom
| | - Nawamin Pinpathomrat
- Respiratory Infections Section, St Mary's Campus, National Heart and Lung Institute, Imperial College London, London, United Kingdom
| | - Freja C M Kirsebom
- Respiratory Infections Section, St Mary's Campus, National Heart and Lung Institute, Imperial College London, London, United Kingdom
| | - Malte Paulsen
- Respiratory Infections Section, St Mary's Campus, National Heart and Lung Institute, Imperial College London, London, United Kingdom
| | - Cecilia Johansson
- Respiratory Infections Section, St Mary's Campus, National Heart and Lung Institute, Imperial College London, London, United Kingdom
| |
Collapse
|
18
|
Habibi MS, Thwaites RS, Chang M, Jozwik A, Paras A, Kirsebom F, Varese A, Owen A, Cuthbertson L, James P, Tunstall T, Nickle D, Hansel TT, Moffatt MF, Johansson C, Chiu C, Openshaw PJM. Neutrophilic inflammation in the respiratory mucosa predisposes to RSV infection. Science 2020; 370:eaba9301. [PMID: 33033192 PMCID: PMC7613218 DOI: 10.1126/science.aba9301] [Citation(s) in RCA: 82] [Impact Index Per Article: 20.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2020] [Revised: 06/30/2020] [Accepted: 08/19/2020] [Indexed: 12/12/2022]
Abstract
The variable outcome of viral exposure is only partially explained by known factors. We administered respiratory syncytial virus (RSV) to 58 volunteers, of whom 57% became infected. Mucosal neutrophil activation before exposure was highly predictive of symptomatic RSV disease. This was associated with a rapid, presymptomatic decline in mucosal interleukin-17A (IL-17A) and other mediators. Conversely, those who resisted infection showed presymptomatic activation of IL-17- and tumor necrosis factor-related pathways. Vulnerability to infection was not associated with baseline microbiome but was reproduced in mice by preinfection chemokine-driven airway recruitment of neutrophils, which caused enhanced disease mediated by pulmonary CD8+ T cell infiltration. Thus, mucosal neutrophilic inflammation at the time of RSV exposure enhances susceptibility, revealing dynamic, time-dependent local immune responses before symptom onset and explaining the as-yet unpredictable outcomes of pathogen exposure.
Collapse
Affiliation(s)
| | - Ryan S Thwaites
- National Heart and Lung Institute, Imperial College London, London, UK
| | | | - Agnieszka Jozwik
- National Heart and Lung Institute, Imperial College London, London, UK
| | - Allan Paras
- National Heart and Lung Institute, Imperial College London, London, UK
| | - Freja Kirsebom
- National Heart and Lung Institute, Imperial College London, London, UK
| | - Augusto Varese
- National Heart and Lung Institute, Imperial College London, London, UK
| | - Amber Owen
- National Heart and Lung Institute, Imperial College London, London, UK
| | - Leah Cuthbertson
- National Heart and Lung Institute, Imperial College London, London, UK
| | - Phillip James
- National Heart and Lung Institute, Imperial College London, London, UK
| | | | - David Nickle
- Genetics & Pharmacogenomics, Department of Translational Medicine, Merck & Co., Inc., Boston, MA, USA
| | - Trevor T Hansel
- National Heart and Lung Institute, Imperial College London, London, UK
| | - Miriam F Moffatt
- National Heart and Lung Institute, Imperial College London, London, UK
| | - Cecilia Johansson
- National Heart and Lung Institute, Imperial College London, London, UK.
| | - Christopher Chiu
- Department of Infectious Disease, Imperial College London, London, UK.
| | | |
Collapse
|
19
|
Remes Lenicov F, Paletta AL, Gonzalez Prinz M, Varese A, Pavillet CE, Lopez Malizia Á, Sabatté J, Geffner JR, Ceballos A. Prostaglandin E2 Antagonizes TGF-β Actions During the Differentiation of Monocytes Into Dendritic Cells. Front Immunol 2018; 9:1441. [PMID: 29988364 PMCID: PMC6023975 DOI: 10.3389/fimmu.2018.01441] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2018] [Accepted: 06/11/2018] [Indexed: 12/27/2022] Open
Abstract
Inflammatory dendritic cells (DCs) are a distinct subset of DCs that derive from circulating monocytes infiltrating injured tissues. Monocytes can differentiate into DCs with different functional signatures, depending on the presence of environment stimuli. Among these stimuli, transforming growth factor-beta (TGF-β) and prostaglandin E2 (PGE2) have been shown to modulate the differentiation of monocytes into DCs with different phenotypes and functional profiles. In fact, both mediators lead to contrasting outcomes regarding the production of inflammatory and anti-inflammatory cytokines. Previously, we have shown that human semen, which contains high concentrations of PGE2, promoted the differentiation of DCs into a tolerogenic profile through a mechanism dependent on signaling by E-prostanoid receptors 2 and 4. Notably, this effect was induced despite the huge concentration of TGF-β present in semen, suggesting that PGE2 overrides the influence exerted by TGF-β. No previous studies have analyzed the joint actions induced by PGE2 and TGF-β on the function of monocytes or DCs. Here, we analyzed the phenotype and functional profile of monocyte-derived DCs differentiated in the presence of TGF-β and PGE2. DC differentiation guided by TGF-β alone enhanced the expression of CD1a and abrogated LPS-induced expression of IL-10, while differentiation in the presence of PGE2 impaired CD1a expression, preserved CD14 expression, abrogated IL-12 and IL-23 production, stimulated IL-10 production, and promoted the expansion of FoxP3+ regulatory T cells in a mixed lymphocyte reaction. Interestingly, DCs differentiated in the presence of TGF-β and PGE2 showed a phenotype and functional profile closely resembling those induced by PGE2 alone. Finally, we found that PGE2 inhibited TGF-β signaling through an action exerted by EP2 and EP4 receptors coupled to cyclic AMP increase and protein kinase A activity. These results indicate that PGE2 suppresses the influence exerted by TGF-β during DC differentiation, imprinting a tolerogenic signature. High concentrations of TGF-β and PGE2 are usually found in infectious, autoimmune, and neoplastic diseases. Our observations suggest that in these scenarios PGE2 might play a mandatory role in the acquisition of a regulatory profile by DCs.
Collapse
Affiliation(s)
- Federico Remes Lenicov
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Ana Luz Paletta
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Melina Gonzalez Prinz
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Augusto Varese
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Clara E Pavillet
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Álvaro Lopez Malizia
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Juan Sabatté
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Jorge Raul Geffner
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Ana Ceballos
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires, Buenos Aires, Argentina
| |
Collapse
|
20
|
Dantas E, Erra Díaz F, Pereyra Gerber P, Merlotti A, Varese A, Ostrowski M, Sabatté J, Geffner J. Low pH impairs complement-dependent cytotoxicity against IgG-coated target cells. Oncotarget 2018; 7:74203-74216. [PMID: 27716623 PMCID: PMC5342046 DOI: 10.18632/oncotarget.12412] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2016] [Accepted: 09/20/2016] [Indexed: 12/25/2022] Open
Abstract
Local acidosis is a common feature of allergic, vascular, autoimmune, and cancer diseases. However, few studies have addressed the effect of extracellular pH on the immune response. Here, we analyzed whether low pH could modulate complement-dependent cytotoxicity (CDC) against IgG-coated cells. Using human serum as a complement source, we found that extracellular pH values of 5.5 and 6.0 strongly inhibit CDC against either B lymphoblast cell lines coated with the chimeric anti-CD20 mAb rituximab or PBMCs coated with the humanized anti-CD52 mAb alemtuzumab. Suppression of CDC by low pH was observed either in cells suspended in culture medium or in whole blood assays. Interestingly, not only CDC against IgG-coated cells, but also the activation of the complement system induced by the alternative and lectin pathways was prevented by low pH. Tumor-targeting mAbs represent one of the most successful tools for cancer therapy, however, the use of mAb monotherapy has only modest effects on solid tumors. Our present results suggest that severe acidosis, a hallmark of solid tumors, might impair complement-mediated tumor destruction directed by mAb.
Collapse
Affiliation(s)
- Ezequiel Dantas
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), CONICET, Facultad de Medicina, Universidad de Buenos Aires, Argentina
| | - Fernando Erra Díaz
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), CONICET, Facultad de Medicina, Universidad de Buenos Aires, Argentina
| | - Pehuén Pereyra Gerber
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), CONICET, Facultad de Medicina, Universidad de Buenos Aires, Argentina
| | - Antonela Merlotti
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), CONICET, Facultad de Medicina, Universidad de Buenos Aires, Argentina
| | - Augusto Varese
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), CONICET, Facultad de Medicina, Universidad de Buenos Aires, Argentina
| | - Matías Ostrowski
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), CONICET, Facultad de Medicina, Universidad de Buenos Aires, Argentina
| | - Juan Sabatté
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), CONICET, Facultad de Medicina, Universidad de Buenos Aires, Argentina
| | - Jorge Geffner
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), CONICET, Facultad de Medicina, Universidad de Buenos Aires, Argentina
| |
Collapse
|
21
|
Varese A, Remes Lenicov F, Gonzalez Prinz M, Paletta A, Ernst G, Maeto C, Merlotti A, Sabatte J, Símula S, Holgado MP, Dantas E, Geffner J, Ceballos A. Seminal vesicle fluid increases the efficacy of intravaginal HSV-2 vaccination. Mucosal Immunol 2018; 11:536-548. [PMID: 28745327 DOI: 10.1038/mi.2017.57] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2016] [Accepted: 05/16/2017] [Indexed: 02/04/2023]
Abstract
Once considered merely as a vehicle for spermatozoa, it is now clear that seminal plasma (SP) induces a variety of biological actions on the female reproductive tissues able to modulate the immune response against paternal antigens. To our knowledge, the influence of SP on the immune response against sexually transmitted pathogens has not been yet evaluated. We here analyzed whether the seminal vesicle fluid (SVF), which contributes almost 60% of the SP volume in mice, could modulate the immune response against herpes simplex virus type 2 (HSV-2). We found that SVF does not modify the course of primary infection, but markedly improved protection conferred by vaginal vaccination with inactivated HSV-2 against a lethal challenge. This protective effect was shown to be associated to a robust memory immune response mediated by CD4+ and CD8+ T cells in both the lymph nodes draining the vagina and the vaginal mucosa, the site of viral replication. In contrast with the widespread notion that SP acts as an immunosuppressive agent, our results suggest that SVF might improve the female immune response against sexually transmitted pathogens.
Collapse
Affiliation(s)
- A Varese
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires (UBA) and Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - F Remes Lenicov
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires (UBA) and Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - M Gonzalez Prinz
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires (UBA) and Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - A Paletta
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires (UBA) and Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - G Ernst
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires (UBA) and Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - C Maeto
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires (UBA) and Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - A Merlotti
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires (UBA) and Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - J Sabatte
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires (UBA) and Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - S Símula
- Instituto de Microbiología y Parasitología Médica (IMPaM), UBA-CONICET, Buenos Aires, Argentina
| | - M P Holgado
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires (UBA) and Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - E Dantas
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires (UBA) and Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - J Geffner
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires (UBA) and Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - A Ceballos
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires (UBA) and Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| |
Collapse
|
22
|
Merlotti A, Dantas E, Remes Lenicov F, Ceballos A, Jancic C, Varese A, Rubione J, Stover S, Geffner J, Sabatté J. Fucosylated clusterin in semen promotes the uptake of stress-damaged proteins by dendritic cells via DC-SIGN. Hum Reprod 2015; 30:1545-56. [PMID: 26003430 DOI: 10.1093/humrep/dev113] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2014] [Accepted: 04/27/2015] [Indexed: 01/09/2023] Open
Abstract
STUDY QUESTION Could seminal plasma clusterin play a role in the uptake of stress-damaged proteins by dendritic cells? SUMMARY ANSWER Seminal plasma clusterin, but not serum clusterin, promotes the uptake of stress-damaged proteins by dendritic cells via DC-SIGN. WHAT IS KNOWN ALREADY Clusterin is one of the major extracellular chaperones. It interacts with a variety of stressed proteins to prevent their aggregation, guiding them for receptor-mediated endocytosis and intracellular degradation. The concentration of clusterin in semen is almost 20-fold higher than that found in serum, raising the question about the role of seminal plasma clusterin in reproduction. No previous studies have analyzed whether seminal plasma clusterin has chaperone activity. We have previously shown that seminal plasma clusterin, but not serum clusterin, expresses an extreme abundance of fucosylated glycans. These motifs enable seminal plasma clusterin to bind DC-SIGN with very high affinity. STUDY DESIGN, SIZE, DURATION In vitro experiments were performed to evaluate the ability of seminal plasma clusterin to inhibit the precipitation of stressed proteins, promoting their uptake by dendritic cells via DC-SIGN (a C-type lectin receptor selectively expressed on dendritic cells (DC)). Moreover, the ability of seminal plasma clusterin to modulate the phenotype and function of DCs was also assessed. PARTICIPANTS/MATERIALS, SETTING, METHODS Clusterin was purified from human semen and human serum. Catalase, bovine serum albumin, glutathione S-transferase, and normal human serum were stressed and the ability of seminal plasma clusterin to prevent the precipitation of these proteins, guiding them to DC-SIGN expressed by DCs, was evaluated using a fluorescence-activated cell sorter (FACS). Endocytosis of stressed proteins was analyzed by confocal microscopy and the ability of seminal plasma clusterin-treated DCs to stimulate the proliferation of CD25+FOXP3+CD4+ T cells was also evaluated by FACS. MAIN RESULTS AND THE ROLE OF CHANCE Seminal plasma clusterin interacts with stressed proteins, inhibits their aggregation (P < 0.01) and efficiently targets them to dendritic cells via DC-SIGN (P < 0.01). DCs efficiently endocytosed clusterin-client complexes and sorted them to degradative compartments involved in antigen processing and presentation. Moreover, we also found that the interaction of seminal plasma clusterin with DC-SIGN did not change the phenotype of DCs, but stimulates their ability to induce the expansion of CD25+FOXP3+CD4+ T lymphocytes (P < 0.05 versus control). LIMITATIONS, REASONS FOR CAUTION All the experiments were performed in vitro; hence the relevance of our observations should be validated in vivo. WIDER IMPLICATIONS OF THE FINDINGS Our results suggest that by inducing the endocytosis of stress-damaged proteins by DCs via DC-SIGN, seminal plasma clusterin might promote a tolerogenic response to male antigens, thereby contributing to female tolerance to seminal antigens. STUDY FUNDING/COMPETING INTERESTS The present research was supported by the Consejo Nacional de Investigaciones Científicas y Técnicas, the Buenos Aires University School of Medicine, and the Agencia Nacional de Promoción Científica y Tecnológica (Argentina). The authors have no conflicts of interest to declare.
Collapse
Affiliation(s)
- A Merlotti
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, Universidad de Buenos Aires (UBA)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad Autónoma de Buenos Aires 1121, Argentina
| | - E Dantas
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, Universidad de Buenos Aires (UBA)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad Autónoma de Buenos Aires 1121, Argentina
| | - F Remes Lenicov
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, Universidad de Buenos Aires (UBA)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad Autónoma de Buenos Aires 1121, Argentina
| | - A Ceballos
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, Universidad de Buenos Aires (UBA)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad Autónoma de Buenos Aires 1121, Argentina
| | - C Jancic
- Laboratorio de Inmunología Oncológica, Instituto de Medicina Experimental (IMEX), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET)-Academia Nacional de Medicina, Ciudad Autónoma de Buenos Aires 1425, Argentina
| | - A Varese
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, Universidad de Buenos Aires (UBA)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad Autónoma de Buenos Aires 1121, Argentina
| | - J Rubione
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, Universidad de Buenos Aires (UBA)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad Autónoma de Buenos Aires 1121, Argentina
| | - S Stover
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, Universidad de Buenos Aires (UBA)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad Autónoma de Buenos Aires 1121, Argentina
| | - J Geffner
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, Universidad de Buenos Aires (UBA)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad Autónoma de Buenos Aires 1121, Argentina
| | - J Sabatté
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, Universidad de Buenos Aires (UBA)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad Autónoma de Buenos Aires 1121, Argentina
| |
Collapse
|
23
|
Lenicov FR, Varese A, Merlotti A, Geffner J, Ceballos A. Prostaglandin E2 inhibits the proinflammatory phenotype induced by TGF-β on monocyte-derived dendritic cells. Placenta 2015. [DOI: 10.1016/j.placenta.2015.01.535] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
24
|
Merlotti A, Ruiz MJ, Díaz FE, Dantas E, Varese A, Duette G, Pereyra P, Glenda E, Lenicov FR, Geffner J, Sabatté J. Seminal Plasma Modulates Dendritic Cell Function Favoring the Generation of CD25+/FOXP3+ T-cells. AIDS Res Hum Retroviruses 2014. [DOI: 10.1089/aid.2014.5367.abstract] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Antonela Merlotti
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA, Universidad de Buenos Aires/CONICET, Capital Federal, Argentina
| | - Maria Julia Ruiz
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA, Universidad de Buenos Aires/CONICET, Capital Federal, Argentina
| | - Fernando Erra Díaz
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA, Universidad de Buenos Aires/CONICET, Capital Federal, Argentina
| | - Ezequiel Dantas
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA, Universidad de Buenos Aires/CONICET, Capital Federal, Argentina
| | - Augusto Varese
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA, Universidad de Buenos Aires/CONICET, Capital Federal, Argentina
| | - Gabriel Duette
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA, Universidad de Buenos Aires/CONICET, Capital Federal, Argentina
| | - Pehuen Pereyra
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA, Universidad de Buenos Aires/CONICET, Capital Federal, Argentina
| | - Ernst Glenda
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA, Universidad de Buenos Aires/CONICET, Capital Federal, Argentina
| | - Federico Remes Lenicov
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA, Universidad de Buenos Aires/CONICET, Capital Federal, Argentina
| | - Jorge Geffner
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA, Universidad de Buenos Aires/CONICET, Capital Federal, Argentina
| | - Juan Sabatté
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA, Universidad de Buenos Aires/CONICET, Capital Federal, Argentina
| |
Collapse
|
25
|
Remes Lenicov F, Varese A, Merlotti A, Geffner J, Ceballos A. Prostaglandins in semen compromise the immune response against sexually transmitted pathogens. Med Hypotheses 2014; 83:208-10. [PMID: 24837236 DOI: 10.1016/j.mehy.2014.04.028] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2013] [Accepted: 04/23/2014] [Indexed: 10/25/2022]
Abstract
Seminal plasma is not just a spermatozoa carrier. It induces the expression of inflammatory cytokines and chemokines and a massive infiltration of neutrophils, monocytes and dendritic cells in the female genital mucosa after coitus, enabling the innate immune system to fight against sexually transmitted pathogens. However, exposure to seminal plasma not only turns on an inflammatory response but also induces regulatory mechanisms that allow the fetus (a semiallograft) to grow and develop in the uterus. In mouse models it has been shown that seminal plasma induces the expansion of regulatory T cells specific to seminal Ags in the receptive partner, thus promoting tolerance to paternal alloantigens and avoiding allogeneic fetal rejection. These mechanisms appear to be mainly induced by prostaglandins of the E series (PGE) and TGF-β, which are present at huge concentrations in the seminal plasma. Moreover, we have recently shown that exposure to seminal plasma induces the differentiation of dendritic cells into a tolerogenic profile through a mechanism dependent on the activation of the prostanoid receptors EP2 and EP4 by seminal PGE. Our hypothesis proposes that this tolerogenic response induced by seminal PGE, while promoting fertility by inducing tolerance toward paternal alloantigens, might also compromise the development of the adaptive immune response against sexually transmitted pathogens in the receptive partner.
Collapse
Affiliation(s)
- F Remes Lenicov
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires C1121ABG, Argentina
| | - A Varese
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires C1121ABG, Argentina
| | - A Merlotti
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires C1121ABG, Argentina
| | - J Geffner
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires C1121ABG, Argentina
| | - A Ceballos
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires C1121ABG, Argentina.
| |
Collapse
|
26
|
Bellone E, Di Maria E, Soriani S, Varese A, Doria LL, Ajmar F, Mandich P. A novel mutation (D305V) in the early growth response 2 gene is associated with severe Charcot-Marie-Tooth type 1 disease. Hum Mutat 1999; 14:353-4. [PMID: 10502832 DOI: 10.1002/(sici)1098-1004(199910)14:4<353::aid-humu17>3.0.co;2-4] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Hereditary motor and sensory neuropathies (HMSN) comprises a wide clinical spectrum of related disorders with defects in peripheral nerve myelination. Charcot-Marie-Tooth type 1 (CMT1) is the most common form and is usually a mild disease with onset in the first or second decade; however there is a interfamilial and intrafamilial clinical variation, ranging from asymptomatic expression to severe muscular weakness and atrophy. Recently point mutations in the early growth response 2 gene (EGR2/Krox-20) have been associated with hereditary myelinopathies. We investigated for mutations at the EGR2 gene a patient with severe CMT1 phenotype. Direct sequencing of EGR2 gene showed a heterozygous A T transversion at nucleotide 1064 that predicts an Asp305Val substitution within the first zinc-finger domain. The finding of a novel EGR2 mutation associated with a different phenotype confirms that peripheral neuropathies represent a continuum spectrum of related disorders due to an underlying defect in myelination.
Collapse
Affiliation(s)
- E Bellone
- Department of Oncology, Biology and Genetics, University of Genova, Genova; Italy
| | | | | | | | | | | | | |
Collapse
|
27
|
Mandich P, Mancardi GL, Varese A, Soriani S, Di Maria E, Bellone E, Bado M, Gross L, Windebank AJ, Ajmar F, Schenone A. Congenital hypomyelination due to myelin protein zero Q215X mutation. Ann Neurol 1999; 45:676-8. [PMID: 10319895 DOI: 10.1002/1531-8249(199905)45:5<676::aid-ana21>3.0.co;2-k] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Congenital hypomyelination (CH) is a hereditary demyelinating peripheral neuropathy characterized by early infancy onset, distal muscle weakness, hypotonia, areflexia, and severe slowing of nerve conduction velocities. In the present report, the clinical, morphological, and immunohistochemical features of a CH case and the identification of a mutation in the gene (MPZ) for protein zero (P0) associated with this phenotype are described. This "de novo" mutation in a patient presenting with clinical features quite distinct from those of the more frequent Charcot-Marie-Tooth type 1B disease (CMT1B) or Dejerine-Sottas syndrome (DSS) confirms that CH is allelic with other disorders characterized by a less severe phenotype and a different clinical and neuropathological profile.
Collapse
Affiliation(s)
- P Mandich
- Institute of Biology and Genetics, University of Genoa, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Mandich P, Bellone E, Di Maria E, Pigullo S, Pizzuti A, Schenone A, Soriani S, Varese A, Windebank AJ, Ajmar F. Exclusion of the ninjurin gene as a candidate for hereditary sensory neuropathies type I and type II. Am J Med Genet 1999; 83:409-10. [PMID: 10232753] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
Abstract
Ninjurin is a protein that is up-regulated in Schwann cells and neurons after peripheral nerve injury. Its role in promoting nerve regeneration and its expression in sensory neurons of dorsal root ganglia, as well as the chromosomal localization of the ninjurin gene, makes this gene a candidate for hereditary sensory neuropathies (HSN). In the present report, the human ninjurin gene was analyzed in 17 unrelated patients with HSN type I, two patients with HSN type II, and 10 normal controls, by single strand conformation polymorphism and by direct sequencing. All three exons and splice junctions of the gene were investigated and no mutations were found in our sample of patients. Our results rule out a mutation in the translated region of the ninjurin gene as a cause of HSN type I and type II.
Collapse
Affiliation(s)
- P Mandich
- Department of Oncology, Biology and Genetics, University of Genoa, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Margiotta E, Varese A, Galleano E, Ienna M. [The reimplantation of teeth avulsed by trauma]. Minerva Stomatol 1990; 39:373-7. [PMID: 2381402] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The paper underlines the importance of the reimplantation of teeth following injury in young subjects. The positive results achieved within the short term encourage the extension of this method even to those cases with a poor prognosis (unsuitable means of conservation, long interval between injury and reimplantation). The tooth with in any case serve to retain the space until a prosthetic replacement is inserted when growth has ended.
Collapse
Affiliation(s)
- E Margiotta
- Università degli Studi di Torino, Instituto Policattedra di Clinica Odontostomatologica e Chirurgia Maxillo-Facciale
| | | | | | | |
Collapse
|
30
|
Berio A, Di Stefano A, Calandra A, De Lucchi A, Varese A, Ottolenghi M. [The Toni-Caffey-Silverman syndrome. Personal experience]. Minerva Pediatr 1981; 33:1059-66. [PMID: 7035858] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
|